Grifols S.A. (GRFS) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
PTC Therapeutics (PTCT) has outperformed Grifols S.A. (GRFS) over the past year, losing 1.1% versus a loss of 21.8%. Over five years, PTCT leads with a +66.0% price change compared with -47.3% for GRFS. PTC Therapeutics is the larger company by market cap ($5.28 billion vs $5.10 billion), about 1.0 times the size.
On valuation, Grifols S.A. trades at a lower forward P/E (5.2x vs 23.6x for PTC Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | PTCT |
|---|---|---|
| Share price | $7.50 | $63.23 |
| Market cap | $5.10B | $5.28B |
| 1-day change | -0.27% | -0.74% |
| YTD return | -19.79% | -16.76% |
| 1-year return | -21.79% | -1.06% |
| 5-year return | -47.26% | +66.00% |
| P/E ratio (TTM) | 9.62 | — |
| Forward P/E | 5.20 | 23.62 |
| EPS (TTM) | $0.78 | $-0.65 |
| Dividend yield | 1.40% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | — | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $9.90 | $90.87 |
| 52-week low | $6.96 | $61.23 |
| Distance from 52-week high | -24.24% | -30.42% |
| Analyst consensus | none | buy |
| Avg. price target upside | +44.93% | +60.98% |
| Average volume | 583.27K | 1.15M |
| Shares outstanding | 258.22M | 83.46M |
| Employees | 25,258 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTCT has outperformed GRFS by 20.7 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.40% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
GRFS vs PTCT FAQ
Which is bigger, Grifols S.A. or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.28B compared with $5.10B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, GRFS or PTCT?
PTCT returned -1.06% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Grifols S.A. or PTC Therapeutics?
Grifols S.A. pays a dividend yielding 1.40%, while PTC Therapeutics does not currently pay a regular dividend.
Are Grifols S.A. and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.